147403-52-9

• 常用中文名：1-[(2'-[(乙氧羰基)氧基]脒基)[1,1-联苯基]-4-基)甲基]-2-乙氧基-1H-苯并咪唑-7-甲酸甲酯
• 常用英文名：1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid methyl ester
• CAS号：147403-52-9
• 分子式：C₂₆H₂₂N₄O₅
• 分子量：470.477
• 相关类别： 信号通路 G 蛋白偶联受体/G 蛋白 血管紧张素受体
• 发布时间：2018-07-29 11:50:20
• 更新时间：2026-07-01 09:21:39
• Azilsartanmethylester 是 Azilsartan (HY-14914) 的衍生物,是一种血管紧张素 II 受体拮抗剂,在高血压中发挥重要作用。

名称

• 中文名: 1-[[2-(2,5-二氢-5-氧代-1,2,4-噁二唑-3-基)[1,1-联苯]-4-基]甲基]-2-乙氧基-1H-苯并咪唑-7-羧酸甲酯
• 英文名: methyl 2-ethoxy-3-[[4-[2-(5-oxo-2H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
• 中文别名: 1-[[2'-(2,5-二氢-5-氧代-1,2,4-噁二唑-3-基)[1,1'-联苯]-4-基]甲基]-2-乙氧基; 阿齐沙坦-A04; 美阿沙坦钾杂质20; 阿齐沙坦杂质01; 阿齐沙坦&坎地沙坦酯中间体,1-[(2'-[(乙氧羰基)氧基]脒基)[1,1-联 苯基]-4-基)甲基]-2-乙氧基-1H-苯并 咪唑-7-甲酸甲酯; 阿齐沙; 阿齐沙坦酯杂质D; 1-[[2'-(2,5-二氢-5-氧代-1,2,4-恶二唑-3-基)[1,1-联苯基]-4-基)甲基]-2-乙氧基-1H-苯并咪唑-7-甲酸甲酯; 阿齐沙坦中间体I; 阿齐沙坦INT D; 阿齐沙坦酯杂质; 1-[[2'-(5-氧代-4,5二氢-1,2,4-噁二唑-3基)联苯-4-基]甲基]-1H-苯并咪唑-2-乙氧基-7-羧酸甲酯; 阿齐沙坦酯杂质1; 阿齐沙坦酯杂质D对照品; 阿齐沙坦INT D 阿齐沙坦-A04; 1-[[2'-(2,5-二氢-5-氧代-1,2,4-二唑-3-基)[1,1-联苯]-4-基]甲基]-2-乙氧基-1H-苯并咪唑-7-羧酸甲酯; 甲基-2-乙氧基-1-((2'-(5-氧代-4,5-二氢-1,2,4-恶二唑-3-基)联苯-4-基)甲基)-1H-苯并[D]咪唑-7-羧酸盐; 1-[[2'-(2,5-二氢-5-氧代-1,2,4-噁二唑-3-基)[1,1-联苯]-4-基]甲基]-2-乙氧基-1H-苯并咪唑-7-羧酸甲酯; 美阿沙坦钾U6; 阿齐沙坦-a04; 阿齐沙坦甲酯,10 MM DMSO 溶液; 阿齐沙坦中间体(A2甲酯); 阿齐沙坦中间体2 A2甲酯; 2-乙氧基-1-[(2'-(5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)联苯-4-基]甲基-1H-苯并[D]咪唑-7-甲酸甲酯; 2-乙氧基-1 -((2' - (5-氧代-4,5-二氢-1,2,4-恶二唑-3-基) - [1,1'-联苯] -4-基)甲基 )-1H-苯并[D]咪唑-7-羧酸甲酯; 阿齐沙坦甲酯; 1-[[2'-(2,5-二氢-5-氧代-1,2,4-噁二唑-3-基)[1,1'-联苯]-4-基]甲基]-2-乙氧基(阿齐沙坦杂质); 阿齐沙坦甲酯杂质
• 英文别名: 1-[(2'-[(Ethoxycbonyl)oxy]amidino)[1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-cboxylicacidmethylester; Methyl 2-ethoxy-1-{[2'-(5-hydroxy-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; Azilsan medoxomil-2; AzilstanMedoxoMilInterMediates-2; 1H-BenziMidazole-7-cboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]Methyl] -2-ethoxy-, Methyl ester ISO 9001：2015 REACH; 1-[[2'-(2,5-DIHYDRO-5-OXO-1,2,4-OXADIAZOL-3-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-2-ETHOXY-1H-BENZIMIDAZOLE-7-CBOXYLIC 147-9; 2-Ethoxy-3-[2'-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-cboxylic acid methyl ester; Azilstan medoxomil impurity221; 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester; 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-cboxylate; methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; 1H-BenziMidazole-7-cboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]Methyl] -2-ethoxy-, Methyl ester; methyl 1-[[2'-(4,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate; BEN731; methyl 2-ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-cboxylate; 1H-BenziMidazole-7-cboxylicacid,1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]Methyl]-2-ethoxy-,Methylester; Azilstan Methyl ester; methyl 2-ethoxy-3-[[4-[2-(5-oxo-2H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-cboxylate; methyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl); Azilstan phmaceutical intermediate-2; Azilstan Methyl Ester Impurity; 1-Methyl-[2’-(4,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]-2-ethoxy-1-H-benzimidazole-7-cboxylate; 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazol; 1-((2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)(1,1'-biphenyl)-4-yl)methyl)-2-ethoxy-1h-benzimidazole-7-carboxylic acid methyl ester; intermediates of Azilstan Medoximil; 1H-Benzimidazole-7-Cboxylic Acid-1-[[2'-(2, 5-Dihydro-5-Oxo-1, 2, 4-Oxadiazol-3-yl)[1,1'-Biphenyl]-4-Yl]Methyl]-5-Oxo-1, 2, 4-Oxadiazol-3-yl)[1,1'-Biphenyl]-4-Yl]Methyl]-2-Ethoxy-, Methyl Ester; 1-((2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)(1,1'-biphenyl)-4-yl)methyl)-2-ethoxy-1h-benzimidazole-7-cboxylic acid methyl ester; methyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate; 2-Ethoxy-1-｛[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]Methyl｝-1H-benzo -[d]iMidazole-7- cboxylic acid Methyl ester; Azilstan Methyl Ester, 10 mM in DMSO; (Z)-Methyl 2-ethoxy-3-((2'-(N'-(ethoxycbonyloxy)cbaMiMidoyl)biphenyl-4-yl)Methyl)-3H-benzo[d]iMidazole-4-cboxylate; Methyl 2-ethoxy-1-((2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)Methyl)-1H-benzo[d]iMidazole-7-cboxylate; 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]Methyl] -2-ethoxy-, Methyl ester; methyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-cboxylate; 1-((2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)(1,1'-bipheny; 1- [(2 '- [(ethoxycbonyl) oxy] amidinyl) [1,1-biphenyl] -4-yl) methyl] -2-ethoxy-1H-benzimidazol-7 formate methyl ester; Methyl 1-[[2'-(2,5-Dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)biphenyl-4-yl] methyl] -2-ethoxy-1H-benzimidazole-7-cboxylate; 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'- biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazol; methyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate; 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-cboxylic acid methyl ester; Azilstan impurity U; Methyl 2-ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-1H-benzimidazole-7-carboxylate; Methyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)Methyl)-1H-benzo[d]iMidazole-7-cboxylate; Methyl 2-ethoxy-1-((2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-cboxylate; 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-cboxylic acid methyl ester (Azilstan Impurity); Azilstan Impurity 4 Azilstan Methyl Ester; Azilstan Medoxomil Ester Impurity; Azilstan Acid Methyl Ester; Methyl 2-ethoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-cboxylate; me: 1H-BenziMidazole-7-cboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]Methyl] -2-ethoxy-, Methyl ester; 1H-Benzimidazole-7-carboxylic acid,1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-,methyl ester; 1H-BenziMidazole-7-cboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4; Azilstan impurity 24/Methyl 2-ethoxy-1-((2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-cboxylate; Azilstan medoxomil impurity1; 1H-BenziMidazole-7-cboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl); Azilastan Impurity-4

物化性质

• 密度: 1.4±0.1 g/cm3
• 沸点: 652.0±65.0 °C at 760 mmHg
• 分子式: C₂₆H₂₂N₄O₅
• 分子量: 470.477
• 闪点: 348.1±34.3 °C
• 精确质量: 470.159027
• PSA: 112.24000
• LogP: 4.51
• 蒸汽压: 0.0±2.0 mmHg at 25°C
• 折射率: 1.665
• 储存条件: 室温，干燥

生物活性

• 描述: Azilsartanmethylester 是 Azilsartan (HY-14914) 的衍生物,是一种血管紧张素 II 受体拮抗剂,在高血压中发挥重要作用。
• 相关类别:
  研究领域 >> 心血管疾病
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 血管紧张素受体
• 参考文献:

  [1]. Alison Handley, et al. Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. Clin Exp Hypertens. 2016;38(2):180-8.

安全

• 危害码 (欧洲): Xi

合成路线

上下游产品

上游产品  7
102-09-0 147403-65-4 32315-10-9 503-38-8
530-62-1 105-58-8 616-38-6
下游产品  2
863031-21-4 147403-03-0